Sterling Accuris FY26 revenue rises 16% to ₹231 crore; loss widens 38%

Ahmedabad-based diagnostic chain Sterling Accuris reported ₹230.7 crore in FY26 operating revenue, while net loss widened to ₹32 crore as expenses grew faster than sales. The Morgan Stanley-backed company remained EBITDA-positive and operates 250+ labs and collection centres across 50+ cities.

— Source publishedMon, 24 Aug, 2026, 15:19 IST·First seen Mon, 24 Aug, 2026, 15:21 IST·Source Entrackr · Newsletter

What happened

Ahmedabad-based Sterling Accuris Diagnostics reported FY26 operating revenue of Rs 230.7 crore, up 16%, but its net loss widened 38% to Rs 32 crore as expenses

Key facts

  • FY26 operating revenue: Rs 230.7 crore, up 16% from Rs 198.3 crore in FY25
  • FY26 total income: Rs 233.6 crore
  • FY26 total expenses: Rs 259.5 crore, up 17.5%
  • FY26 net loss: Rs 32 crore, widened 38% from Rs 23.2 crore
  • FY26 EBITDA: Rs 2.8 crore; EBITDA margin: 1.2%
  • Network: 250+ laboratories and collection centres across 50+ cities
  • Total funding raised: $33 million
  • Morgan Stanley stake: 35.64%; Udhay Vi Realty stake: 17%

Why this matters

Sterling Accuris’ 250+ labs and collection centres across 50+ cities create a meaningful platform for regional tuck-ins, partnerships or scale-led consolidation despite continuing bottom-line losses.

What to watch

  • FY27 revenue growth versus the current 16% rate.
  • Whether EBITDA margin expands despite continued network additions.
  • Net-loss trajectory, operating cash flow and any increase in borrowings or equity fundraising.
  • New lab/collection-centre openings, closures or acquisitions.
  • Share of specialized diagnostics, radiology, preventive health and B2B corporate revenue.
  • Pricing pressure and competitive actions from Metropolis, Dr Lal PathLabs, Thyrocare, Vijaya Diagnostic and regional chains.
  • Any Morgan Stanley-led funding round, governance change, IPO preparation or strategic-sale signals.
  • Prioritize higher-margin specialized testing, preventive-health packages and corporate wellness contracts over low-price routine pathology volumes.
  • Rationalize underperforming collection centres and improve hub-and-spoke utilization across cities.
  • Push digital bookings, home sample collection and repeat-patient programs to reduce customer-acquisition costs.
  • Seek selective capital or strategic partnerships if expansion spending cannot be funded from operating cash flow.
  • Increase focus on receivables, test-mix realization and procurement savings to convert EBITDA positivity into cash generation.

Also reported by